Exelixis Inc. (EXEL)

24.32
NASDAQ : Health Technology
Prev Close 24.14
Day Low/High 24.10 / 24.58
52 Wk Low/High 13.42 / 25.31
Avg Volume 4.09M
Exchange NASDAQ
Shares Outstanding 300.13M
Market Cap 7.25B
EPS 2.30
P/E Ratio 10.92
Div & Yield N.A. (N.A)

Latest News

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.

IPO Explosion: Cramer's 'Mad Money' Recap (Wednesday 2/13/19)

IPO Explosion: Cramer's 'Mad Money' Recap (Wednesday 2/13/19)

Jim Cramer sees ripple effects of a storm of IPOs, and is worried about the lack of money coming into the market.

Fitbit, Moderna, Tilray: 'Mad Money' Lightning Round

Fitbit, Moderna, Tilray: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Fitbit, Moderna, Tilray, Exelixis, Maxar Technology, International Paper and more.

Exelixis Rises as Fourth-Quarter Earnings Beat Estimates

Exelixis Rises as Fourth-Quarter Earnings Beat Estimates

The company reports fourth-quarter earnings above analysts' forecasts amid strong revenue from collaboration agreements and royalty payments to distribute its drugs.

These 'Small Ball' Names Will Outperform the Market in 2019

These 'Small Ball' Names Will Outperform the Market in 2019

Investors are already more focused on what lies ahead when Q1 results start in early April.

Exelixis Announces Fourth Quarter And Full Year 2018 Financial Results And Provides Corporate Update

Exelixis Announces Fourth Quarter And Full Year 2018 Financial Results And Provides Corporate Update

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and full year 2018 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.

Exelixis To Initiate Phase 1 Clinical Development Of XL092, First New Compound To Enter The Clinic From Reinitiated Discovery Efforts

Exelixis To Initiate Phase 1 Clinical Development Of XL092, First New Compound To Enter The Clinic From Reinitiated Discovery Efforts

Exelixis, Inc. (Nasdaq: EXEL) today announced it is initiating phase 1 clinical development for XL092, the first internally-discovered Exelixis compound to enter the clinic following the company's reinitiation of drug discovery activities.

Exelixis To Present At The Guggenheim Healthcare Talks Idea Forum / Oncology Day 2019 On February 14, 2019

Exelixis To Present At The Guggenheim Healthcare Talks Idea Forum / Oncology Day 2019 On February 14, 2019

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Exelixis To Release Fourth Quarter And Full Year 2018 Financial Results On Tuesday, February 12, 2019

Exelixis To Release Fourth Quarter And Full Year 2018 Financial Results On Tuesday, February 12, 2019

Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2018 financial results will be released on Tuesday, February 12, 2019 after the markets close.

Breaking Down Citigroup Earnings: Cramer's 'Mad Money' Recap (Monday 1/14/19)

Breaking Down Citigroup Earnings: Cramer's 'Mad Money' Recap (Monday 1/14/19)

We may be so worried about the state of the global economy that we're missing some great opportunities, Jim Cramer says.

CABOMETYX® Tablets 60 Mg, 40 Mg, 20 Mg (Photo: Business Wire)

CABOMETYX® Tablets 60 Mg, 40 Mg, 20 Mg (Photo: Business Wire)

Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.

My 2 Top Stock Picks for 2019

My 2 Top Stock Picks for 2019

It's probably no surprise that my picks for 2019 come from the biotech/biopharma space.

Exelixis' Collaborator Daiichi Sankyo Receives Regulatory Approval For MINNEBRO™ (Esaxerenone) Tablets For The Treatment Of Hypertension In Japan

Exelixis' Collaborator Daiichi Sankyo Receives Regulatory Approval For MINNEBRO™ (Esaxerenone) Tablets For The Treatment Of Hypertension In Japan

Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Daiichi Sankyo Company, Limited ("Daiichi Sankyo") received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for esaxerenone tablets, MINNEBRO™ 1.

Celgene Deal Gets the M&A Ball Rolling in the New Year

Celgene Deal Gets the M&A Ball Rolling in the New Year

It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: DNR, EXEL, GIL, HF, ITGR, TEF Downgrades: CERC, FSB, PED, QTNA Initiations: URGN Read on to get TheStreet Quant Ratings' detailed report:

3 Profitable Small Biotech Names to Consider

3 Profitable Small Biotech Names to Consider

Exelixis Inc., ANI Pharmaceuticals and Supernus Pharmaceuticals should not need to raise more capital in the foreseeable future.

Exelixis And Ipsen Initiate Phase 3 Pivotal Trial (COSMIC-312) Of Cabozantinib In Combination With Atezolizumab Versus Sorafenib In Previously Untreated Advanced Hepatocellular Carcinoma

Exelixis And Ipsen Initiate Phase 3 Pivotal Trial (COSMIC-312) Of Cabozantinib In Combination With Atezolizumab Versus Sorafenib In Previously Untreated Advanced Hepatocellular Carcinoma

Exelixis, Inc. (Nasdaq:EXEL) and Ipsen (Euronext:IPN; ADR:IPSEY) today announced the initiation of COSMIC-312, a phase 3 pivotal trial of cabozantinib (CABOMETYX ®) in combination with atezolizumab (TECENTRIQ ®) versus sorafenib in previously untreated...

Exelixis Announces Webcasts Of Investor Conference Presentations In November

Exelixis Announces Webcasts Of Investor Conference Presentations In November

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.

Here's How I'm Playing Biotech Now

Here's How I'm Playing Biotech Now

I continue to deploy 'dry powder' into the biotech sector on dips using Buy-Write option strategies.

Exelixis' Partner Ipsen Receives European Commission Approval For CABOMETYX® (cabozantinib) Tablets For The Treatment Of Hepatocellular Carcinoma In Adults Previously Treated With Sorafenib

Exelixis' Partner Ipsen Receives European Commission Approval For CABOMETYX® (cabozantinib) Tablets For The Treatment Of Hepatocellular Carcinoma In Adults Previously Treated With Sorafenib

Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX ® (cabozantinib) tablets as a monotherapy for hepatocellular carcinoma (HCC) in adults who have previously been treated...

Exelixis To Present At The Stifel 2018 Healthcare Conference On November 13, 2018

Exelixis To Present At The Stifel 2018 Healthcare Conference On November 13, 2018

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Small Biotechs Finally Join in Market Rebound

Small Biotechs Finally Join in Market Rebound

Exelixis Inc. and Aratana Therapeutics in particular surge after posting solid results Thursday.

Exelixis Announces Third Quarter 2018 Financial Results And Provides Corporate Update

Exelixis Announces Third Quarter 2018 Financial Results And Provides Corporate Update

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2018 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.

Noteworthy Monday Option Activity: EXEL, CONN, EBS

Noteworthy Monday Option Activity: EXEL, CONN, EBS

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Exelixis Inc , where a total volume of 22,454 contracts has been traded thus far today, a contract volume which is representative of approximately 2.2 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 66.7% of EXEL's average daily trading volume over the past month, of 3.4 million shares.

Tech Doesn't Have Good Defense: Cramer's 'Mad Money' Recap (Thursday 9/6/18)

Tech Doesn't Have Good Defense: Cramer's 'Mad Money' Recap (Thursday 9/6/18)

Jim Cramer, celebrating the opening of the NFL season, says this is just another day of total tech mayhem.

United Parcel Service, TJX Companies: 'Mad Money' Lightning Round

United Parcel Service, TJX Companies: 'Mad Money' Lightning Round

Jim Cramer takes a look at United Parcel Service, TJX Companies, Anheuser-Busch InBev, Fiat Chrysler, AbbVie, Nvidia, Excelixis, Bank of America, Endo Pharmaceutical and more.

Exelixis Announces Results From The Dose-Escalation Stage Of The Phase 1b COSMIC-021 Study Of Cabozantinib In Combination With Atezolizumab In Previously Untreated Advanced Renal Cell Carcinoma

Exelixis Announces Results From The Dose-Escalation Stage Of The Phase 1b COSMIC-021 Study Of Cabozantinib In Combination With Atezolizumab In Previously Untreated Advanced Renal Cell Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) today announced results from the dose-escalation stage of the phase 1b COSMIC-021 study of cabozantinib in combination with atezolizumab in previously untreated advanced renal cell carcinoma (RCC).

TheStreet Quant Rating: B (Buy)